|
|
|
Volumn 14, Issue 3, 2001, Pages 175-180
|
|
Smoking-related lung disease: Prospects for new drug therapy. Highlights from the symposium of the Society for Medicines Research, held March 14, 2001, in London, U.K.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMFEBUTAMONE;
BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT;
CHEMOTACTIC FACTOR;
CILOMILAST;
FORMOTEROL;
HYDROXOCOBALAMIN;
INFLIXIMAB;
IPRATROPIUM BROMIDE;
IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE;
ISOTRETINOIN;
MANGANESEDICHLORO(3,10,13,20,26 PENTAAZATETRACYCLO[20.3.1.0(4,9).0(14,19)] 1(26),22(23),24 HEXACOSATRIENE);
MONOCLONAL ANTIBODY;
NITRIC OXIDE SYNTHASE INHIBITOR;
PHOSPHODIESTERASE INHIBITOR;
PROTEINASE INHIBITOR;
REACTIVE OXYGEN METABOLITE;
RETINOID DERIVATIVE;
RO 444753;
SALBUTAMOL;
SALMETEROL;
SB 332235;
SC 537;
SIBENADET;
TIOTROPIUM BROMIDE;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
CHRONIC OBSTRUCTIVE LUNG DISEASE;
CLINICAL TRIAL;
CONFERENCE PAPER;
DISEASE ASSOCIATION;
DRUG RESEARCH;
DRUG STRUCTURE;
HUMAN;
MEDICAL SOCIETY;
SMOKING;
UNITED KINGDOM;
|
|
EID: 0034952246
PISSN: 02140934
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (3)
|
|
References (2)
|
